A TPU compounder, not a converter
Nilun develops and manufactures thermoplastic polyurethane pellets for five application lines. We do not make catheters, cables or shoe soles — we make the material those products are built from.
The work is formulation and synthesis. Hardness from 60 Shore A to 85 Shore D, across six chemistry types, each tuned to a different failure mode: hydrolysis in a steam cycle, yellowing under UV, flame spread in a cable bundle, rebound after foaming.
That range is why the catalogue is published grade by grade rather than as a brochure. A catheter shaft and a footwear midsole start from the same reactor chemistry and diverge in hardness, additives and compliance route. Publishing all forty-one lets an engineer find the one that fits instead of asking us to guess.
For medical devices we hold a China National Master File (MAF) filing, which supports a customer's own device registration rather than replacing it. Biocompatibility is demonstrated case by case — including a completed 52-week implantation study — and the medical TPU range is covered across 70A–85D. Grade selection, biocompatibility data and change control are handled per application; the first step is always a conversation about the intended use.
The plant occupies 18,000 m² of building area, running a polymerization line, a compounding line and a pilot line, backed by complete testing and laboratory equipment. Annual TPU capacity is 60,000 tonnes.
At a glance
Certifications & compliance
Confirmed certifications and compliance for the Nilun TPU range.
- Full-range medical TPU certification (70A–85D)
- China National Master File (MAF)
- USP Class VI
- ISO 10993 series
- ISO 9001 quality management
- ISO 14001 environmental management
- ISO 45001 occupational health & safety
- RoHS
- REACH
Shanghai Science & Technology Progress Award (Second Prize)
Milestones
- 2021
Company founded in Fengxian, Shanghai, and the specialty TPU plant project launched.
- 2023
Named a lead unit in the MIIT biomedical-materials programme, covering import substitution of TPU for artificial blood vessels.
- 2024
Full-range medical TPU certification completed across 70A–85D — the second supplier worldwide to hold a full range — followed by national master file (MAF) registration of the implant-grade polycarbonate grades.
- 2025
Shanghai Science & Technology Progress Award, Second Prize (certificate 20254032-2-D03); recognised under the MOST Young Scientist programme and the Shanghai domestic-substitution special project.
Company information
Corporate profile, financing history and certifications are maintained on the corporate site. This site is the product and technical surface.